Analysts think CNTB stock price could increase by 310%
Jun 14, 2024, 6:30 AM
-23.56%
What does CNTB do
Connect Biopharma Holdings Ltd., headquartered in San Diego, develops therapies for T cell-driven inflammatory diseases and launched its IPO on March 19, 2021. The company's leading products, including CBP-201 and CBP-307, target conditions such as atopic dermatitis, asthma, and ulcerative colitis.
4 analysts think CNTB stock price will increase by 310.34%. The current median analyst target is $7.14 compared to a current stock price of $1.74. The lowest analysts target is $6.06 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.